A kidney infection, also known as
pyelonephritis, is a type of urinary tract infection, wherein one or both
kidneys are infected. The infection is caused by bacteria or a virus that
commonly begins to infect urinary bladder and moves up to one or both the kidneys.
Read Report Overview
- https://www.transparencymarketresearch.com/pyelonephritis-treatment-market.html
Signs or symptoms of
pyelonephritis can vary depending on age and could include confusion & back
pain, chills & high fever, nausea & vomiting, back, side, and groin
pain, and painful urination. Predisposing factors of pyelonephritis include
kidney stones, weakened immune system, structural problems of the urinary
tract, urine reflux problems, and damage to nerves around the bladder.
The global pyelonephritis
treatment market is projected to witness strong growth during the forecast
period due to high prevalence and incidence rates of pyelonephritis disorder
across the globe. Around 200,000 hospitalizations for acute pyelonephritis are
reported in the U.S. each year. Hence, a large population base with kidney
infection across the globe is expected to drive the global pyelonephritis
treatment market during the forecast period.
Request Brochure of
Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56181
High per capita health care
expenditure in developed countries, availability of technologically advanced
hemodialysis systems, and favorable medical reimbursement in developed
countries are anticipated to boost the pyelonephritis treatment market during
the forecast period. Moreover, rise in demand for kidney care centers in
countries such as India, China, Brazil, and South Korea is expected to drive
the global pyelonephritis treatment market.
The global pyelonephritis
treatment market can be segmented based on treatment algorithm and region. In
terms of treatment algorithm, the pyelonephritis treatment market can be
classified into initial pyelonephritis, acute pyelonephritis, and ongoing
pyelonephritis. The pipeline of drugs for nephrotic syndrome is relatively
small, with around 15 products in active development at public and private
research centers and industries.
Request for Custom
Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56181
Antibiotics is the initial
treatment for pyelonephritis. Several new antibiotics are expected to be
launched during the forecast period. These novel drugs will not only provide
additional treatment options, especially for pyelonephritis treatment, but also
drive market size, as these products will have higher price points than the
generic products currently dominating the pyelonephritis treatment market. High
prevalence of antibiotic resistance, particularly of strains with resistance,
will drive pyelonephritis treatment market size, as treatment options for those
infections will include non-generic antibiotics.
Companies are presenting their
pipeline molecule results in their annual meetings and conferences. In May
2018, Melinta Therapeutics highlighted Vabomere at making a difference in
infectious diseases (MAD-ID) 2018 Annual Meeting. In August 2018, Entasis
Therapeutics announced a positive topline results from phase II of ETX2514SUL
in patients with complicated urinary tract infections including acute
pyelonephritis.
In terms of region, North America
dominated the global pyelonephritis treatment market in 2017. The market in the
region is primarily powered by the U.S., which has witnessed highest incidence
of the disease. State-of-the-art health care facilities that offer latest and
the best treatment, high per capita health care spending among people, and
awareness about available treatments for pyelonephritis augment the market in
the region.
Pre Book Pyelonephritis
Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=56181<ype=S
Europe is another key market for
pyelonephritis treatment. Germany and the U.K. are the major markets in the
region. Greater degree of awareness with respect to overall kidney health has
led to a large number of people undergoing screening for kidney diseases.
Emerging economies such as India and China are the key markets for
pyelonephritis treatment in Asia Pacific. Rise in population contributed to the
growth of the pyelonephritis treatment market in the region.
Major players having
pyelonephritis treatment products in the pipeline are Merck & Co, Inc.,
Wockhardt Ltd., AstraZeneca plc, Entasis Therapeutics, Inc., Iterum
Therapeutics plc, Meiji Seika Pharma Co. Ltd., Paratek Pharmaceuticals, Inc.,
Nabriva Therapeutics plc, MerLion Pharmaceuticals Pte. Ltd., and Melinta
Therapeutics, Inc.
About Us
Transparency Market Research is a
global market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for several decision makers.
Our experienced team of analysts, researchers, and consultants use proprietary
data sources and various tools and techniques to gather and analyze
information.
Our data repository is
continuously updated and revised by a team of research experts so that it always
reflects latest trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research material
for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free:
866-552-3453
